Cargando…
Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study
INTRODUCTION: Bone loss is a major issue in patients affected by Duchenne muscular dystrophy (DMD), a rare musculoskeletal disorder, particularly in those treated with glucocorticoids (GCs). We aimed to assess the effectiveness of neridronate in terms of bone mineral density (BMD) changes in this po...
Autores principales: | Moretti, Antimo, Liguori, Sara, Paoletta, Marco, Gimigliano, Francesca, Iolascon, Giovanni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239967/ https://www.ncbi.nlm.nih.gov/pubmed/35614293 http://dx.doi.org/10.1007/s12325-022-02179-1 |
Ejemplares similares
-
Bone fragility: conceptual framework, therapeutic implications, and COVID-19-related issues
por: Iolascon, Giovanni, et al.
Publicado: (2022) -
The Rationale for Using Neridronate in Musculoskeletal Disorders: From Metabolic Bone Diseases to Musculoskeletal Pain
por: Iolascon, Giovanni, et al.
Publicado: (2022) -
Pain and Motor Function in Myotonic Dystrophy Type 1: A Cross-Sectional Study
por: Liguori, Sara, et al.
Publicado: (2023) -
Rehabilitation of Neuromuscular Diseases During COVID-19: Pitfalls and Opportunities
por: Liguori, Sara, et al.
Publicado: (2021) -
Bone fragility during the COVID-19 pandemic: the role of macro- and
micronutrients
por: Moretti, Antimo, et al.
Publicado: (2023)